Report cover image

Global TIGIT Therapies Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 194 Pages
SKU # APRC20361692

Description

Summary

According to APO Research, The global TIGIT Therapies market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for TIGIT Therapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for TIGIT Therapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for TIGIT Therapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for TIGIT Therapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of TIGIT Therapies include Arcus, Astellas, BMS, Compugen, Mereo BioPharma, Seattle Genetics, AstraZeneca, BeiGene and Hengrui Medicine, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for TIGIT Therapies, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of TIGIT Therapies, also provides the revenue of main regions and countries. Of the upcoming market potential for TIGIT Therapies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the TIGIT Therapies revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global TIGIT Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for TIGIT Therapies revenue, projected growth trends, production technology, application and end-user industry.

TIGIT Therapies Segment by Company

Arcus
Astellas
BMS
Compugen
Mereo BioPharma
Seattle Genetics
AstraZeneca
BeiGene
Hengrui Medicine
Junshi Biosciences
Roche
Merck
Innovent Biologics
TIGIT Therapies Segment by Type

Monotherapy
Combination Therapy
TIGIT Therapies Segment by Application

Cell Carcinoma
Solid Tumor
TIGIT Therapies Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TIGIT Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of TIGIT Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TIGIT Therapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of TIGIT Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of TIGIT Therapies company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, TIGIT Therapies revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 TIGIT Therapies Market by Type
1.2.1 Global TIGIT Therapies Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Monotherapy
1.2.3 Combination Therapy
1.3 TIGIT Therapies Market by Application
1.3.1 Global TIGIT Therapies Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cell Carcinoma
1.3.3 Solid Tumor
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 TIGIT Therapies Market Dynamics
2.1 TIGIT Therapies Industry Trends
2.2 TIGIT Therapies Industry Drivers
2.3 TIGIT Therapies Industry Opportunities and Challenges
2.4 TIGIT Therapies Industry Restraints
3 Global Growth Perspective
3.1 Global TIGIT Therapies Market Perspective (2020-2031)
3.2 Global TIGIT Therapies Growth Trends by Region
3.2.1 Global TIGIT Therapies Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global TIGIT Therapies Market Size by Region (2020-2025)
3.2.3 Global TIGIT Therapies Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global TIGIT Therapies Revenue by Players
4.1.1 Global TIGIT Therapies Revenue by Players (2020-2025)
4.1.2 Global TIGIT Therapies Revenue Market Share by Players (2020-2025)
4.1.3 Global TIGIT Therapies Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global TIGIT Therapies Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global TIGIT Therapies Key Players Headquarters & Area Served
4.4 Global TIGIT Therapies Players, Product Type & Application
4.5 Global TIGIT Therapies Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global TIGIT Therapies Market CR5 and HHI
4.6.3 2024 TIGIT Therapies Tier 1, Tier 2, and Tier 3
5 TIGIT Therapies Market Size by Type
5.1 Global TIGIT Therapies Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global TIGIT Therapies Revenue by Type (2020-2031)
5.3 Global TIGIT Therapies Revenue Market Share by Type (2020-2031)
6 TIGIT Therapies Market Size by Application
6.1 Global TIGIT Therapies Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global TIGIT Therapies Revenue by Application (2020-2031)
6.3 Global TIGIT Therapies Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Arcus
7.1.1 Arcus Comapny Information
7.1.2 Arcus Business Overview
7.1.3 Arcus TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.1.4 Arcus TIGIT Therapies Product Portfolio
7.1.5 Arcus Recent Developments
7.2 Astellas
7.2.1 Astellas Comapny Information
7.2.2 Astellas Business Overview
7.2.3 Astellas TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.2.4 Astellas TIGIT Therapies Product Portfolio
7.2.5 Astellas Recent Developments
7.3 BMS
7.3.1 BMS Comapny Information
7.3.2 BMS Business Overview
7.3.3 BMS TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.3.4 BMS TIGIT Therapies Product Portfolio
7.3.5 BMS Recent Developments
7.4 Compugen
7.4.1 Compugen Comapny Information
7.4.2 Compugen Business Overview
7.4.3 Compugen TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.4.4 Compugen TIGIT Therapies Product Portfolio
7.4.5 Compugen Recent Developments
7.5 Mereo BioPharma
7.5.1 Mereo BioPharma Comapny Information
7.5.2 Mereo BioPharma Business Overview
7.5.3 Mereo BioPharma TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.5.4 Mereo BioPharma TIGIT Therapies Product Portfolio
7.5.5 Mereo BioPharma Recent Developments
7.6 Seattle Genetics
7.6.1 Seattle Genetics Comapny Information
7.6.2 Seattle Genetics Business Overview
7.6.3 Seattle Genetics TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.6.4 Seattle Genetics TIGIT Therapies Product Portfolio
7.6.5 Seattle Genetics Recent Developments
7.7 AstraZeneca
7.7.1 AstraZeneca Comapny Information
7.7.2 AstraZeneca Business Overview
7.7.3 AstraZeneca TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.7.4 AstraZeneca TIGIT Therapies Product Portfolio
7.7.5 AstraZeneca Recent Developments
7.8 BeiGene
7.8.1 BeiGene Comapny Information
7.8.2 BeiGene Business Overview
7.8.3 BeiGene TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.8.4 BeiGene TIGIT Therapies Product Portfolio
7.8.5 BeiGene Recent Developments
7.9 Hengrui Medicine
7.9.1 Hengrui Medicine Comapny Information
7.9.2 Hengrui Medicine Business Overview
7.9.3 Hengrui Medicine TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.9.4 Hengrui Medicine TIGIT Therapies Product Portfolio
7.9.5 Hengrui Medicine Recent Developments
7.10 Junshi Biosciences
7.10.1 Junshi Biosciences Comapny Information
7.10.2 Junshi Biosciences Business Overview
7.10.3 Junshi Biosciences TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.10.4 Junshi Biosciences TIGIT Therapies Product Portfolio
7.10.5 Junshi Biosciences Recent Developments
7.11 Roche
7.11.1 Roche Comapny Information
7.11.2 Roche Business Overview
7.11.3 Roche TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.11.4 Roche TIGIT Therapies Product Portfolio
7.11.5 Roche Recent Developments
7.12 Merck
7.12.1 Merck Comapny Information
7.12.2 Merck Business Overview
7.12.3 Merck TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.12.4 Merck TIGIT Therapies Product Portfolio
7.12.5 Merck Recent Developments
7.13 Innovent Biologics
7.13.1 Innovent Biologics Comapny Information
7.13.2 Innovent Biologics Business Overview
7.13.3 Innovent Biologics TIGIT Therapies Revenue and Gross Margin (2020-2025)
7.13.4 Innovent Biologics TIGIT Therapies Product Portfolio
7.13.5 Innovent Biologics Recent Developments
8 North America
8.1 North America TIGIT Therapies Revenue (2020-2031)
8.2 North America TIGIT Therapies Revenue by Type (2020-2031)
8.2.1 North America TIGIT Therapies Revenue by Type (2020-2025)
8.2.2 North America TIGIT Therapies Revenue by Type (2026-2031)
8.3 North America TIGIT Therapies Revenue Share by Type (2020-2031)
8.4 North America TIGIT Therapies Revenue by Application (2020-2031)
8.4.1 North America TIGIT Therapies Revenue by Application (2020-2025)
8.4.2 North America TIGIT Therapies Revenue by Application (2026-2031)
8.5 North America TIGIT Therapies Revenue Share by Application (2020-2031)
8.6 North America TIGIT Therapies Revenue by Country
8.6.1 North America TIGIT Therapies Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America TIGIT Therapies Revenue by Country (2020-2025)
8.6.3 North America TIGIT Therapies Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe TIGIT Therapies Revenue (2020-2031)
9.2 Europe TIGIT Therapies Revenue by Type (2020-2031)
9.2.1 Europe TIGIT Therapies Revenue by Type (2020-2025)
9.2.2 Europe TIGIT Therapies Revenue by Type (2026-2031)
9.3 Europe TIGIT Therapies Revenue Share by Type (2020-2031)
9.4 Europe TIGIT Therapies Revenue by Application (2020-2031)
9.4.1 Europe TIGIT Therapies Revenue by Application (2020-2025)
9.4.2 Europe TIGIT Therapies Revenue by Application (2026-2031)
9.5 Europe TIGIT Therapies Revenue Share by Application (2020-2031)
9.6 Europe TIGIT Therapies Revenue by Country
9.6.1 Europe TIGIT Therapies Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe TIGIT Therapies Revenue by Country (2020-2025)
9.6.3 Europe TIGIT Therapies Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China TIGIT Therapies Revenue (2020-2031)
10.2 China TIGIT Therapies Revenue by Type (2020-2031)
10.2.1 China TIGIT Therapies Revenue by Type (2020-2025)
10.2.2 China TIGIT Therapies Revenue by Type (2026-2031)
10.3 China TIGIT Therapies Revenue Share by Type (2020-2031)
10.4 China TIGIT Therapies Revenue by Application (2020-2031)
10.4.1 China TIGIT Therapies Revenue by Application (2020-2025)
10.4.2 China TIGIT Therapies Revenue by Application (2026-2031)
10.5 China TIGIT Therapies Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia TIGIT Therapies Revenue (2020-2031)
11.2 Asia TIGIT Therapies Revenue by Type (2020-2031)
11.2.1 Asia TIGIT Therapies Revenue by Type (2020-2025)
11.2.2 Asia TIGIT Therapies Revenue by Type (2026-2031)
11.3 Asia TIGIT Therapies Revenue Share by Type (2020-2031)
11.4 Asia TIGIT Therapies Revenue by Application (2020-2031)
11.4.1 Asia TIGIT Therapies Revenue by Application (2020-2025)
11.4.2 Asia TIGIT Therapies Revenue by Application (2026-2031)
11.5 Asia TIGIT Therapies Revenue Share by Application (2020-2031)
11.6 Asia TIGIT Therapies Revenue by Country
11.6.1 Asia TIGIT Therapies Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia TIGIT Therapies Revenue by Country (2020-2025)
11.6.3 Asia TIGIT Therapies Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA TIGIT Therapies Revenue (2020-2031)
12.2 SAMEA TIGIT Therapies Revenue by Type (2020-2031)
12.2.1 SAMEA TIGIT Therapies Revenue by Type (2020-2025)
12.2.2 SAMEA TIGIT Therapies Revenue by Type (2026-2031)
12.3 SAMEA TIGIT Therapies Revenue Share by Type (2020-2031)
12.4 SAMEA TIGIT Therapies Revenue by Application (2020-2031)
12.4.1 SAMEA TIGIT Therapies Revenue by Application (2020-2025)
12.4.2 SAMEA TIGIT Therapies Revenue by Application (2026-2031)
12.5 SAMEA TIGIT Therapies Revenue Share by Application (2020-2031)
12.6 SAMEA TIGIT Therapies Revenue by Country
12.6.1 SAMEA TIGIT Therapies Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA TIGIT Therapies Revenue by Country (2020-2025)
12.6.3 SAMEA TIGIT Therapies Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.